Blog
RSS FeedPosted by Michael Wonder on 22 Jan 2020
Supporting innovative medicines funding in Scotland
21 January 2020 - Scotland receives superb value from the latest medicines and vaccines thanks to robust measures which ensure ...
Posted by Michael Wonder on 20 Jan 2020
After 20 years of using economic evaluation, should NICE be considered a methods innovator?
13 January 2020 - NICE is only one of several organisations internationally that uses economic evaluation as part of decision ...
Posted by Michael Wonder on 19 Jan 2020
Is innovation causing accessibility, timing issues for private drug plans?
17 January 2020 - Pharmaceutical companies and private payers can interact in different ways to ensure the right drugs are ...
Posted by Michael Wonder on 19 Jan 2020
Closing the cycle of innovation in health care in Europe
17 January 2020 - Pragmatic or practice-oriented comparative effectiveness trials may be conducted to fill the evidence gaps that are revealed ...
Posted by Michael Wonder on 10 Dec 2019
Pharmacare with no new medicines
10 December 2019 - Meeting with pricing officials shows that government's true goal is to slash prices so low that no ...
Posted by Michael Wonder on 22 Jul 2019
Government to invest £16 million in 'life-saving' medical advances
22 July 2019 - The Government has announced the decision to invest around £16 million in various ‘life-saving’ medical advances, ...
Posted by Michael Wonder on 27 Feb 2019
Economic analysis falls short when it comes to medicines’ value
26 February 2019 - For the past two decades, a plethora of organisations identified by various innocuous acronyms (e.g., NICE) ...
Posted by Michael Wonder on 20 Feb 2019
New drug landscape dominated by high cost medicines
19 February 2019 - The Patented Medicine Prices Review Board, through the National Prescription Drug Utilization Information System research initiative, ...
Posted by Michael Wonder on 14 Feb 2019
Quebec appeals court orders province to restore full coverage of rheumatoid-arthritis drug Remicade
13 February 2019 - Quebec’s highest court has ordered the provincial government to restore full public coverage of Remicade, an ...
Posted by Michael Wonder on 24 Jan 2019
Ottawa’s push for lower drug costs may hurt patients, stunt innovation
24 January 2019 - The federal government’s plan to lower prescription drug prices could impede access and thus limit the ...
Posted by Michael Wonder on 21 Jan 2019
New agreement on branded drugs for the NHS
18 January 2019 - The new Voluntary Scheme for Branded Medicines Pricing and Access began on 1 January and was ...
Posted by Michael Wonder on 07 Dec 2018
Underuse of innovative medicines in Germany: A justification for government intervention?
6 December 2018 - The German market for innovative medicines is characterised by simultaneous underuse and overuse. ...
Posted by Michael Wonder on 04 Dec 2018
Flexibility on cancer drugs approval will foster innovation
4 December 2018 - Between 2000 and 2016, no new drugs were approved for cancers of the brain, and there were ...
Posted by Michael Wonder on 10 Oct 2018
New drugs: how much are governments paying for innovation?
10 October 2018 - The medical innovation debate is also heated up due to the ongoing discussion on Health Technology Assessments. ...
Posted by Michael Wonder on 29 Aug 2018
Developing tools to support digital health and medtech innovation
8 August 2018 - NICE is involved in two key initiatives with national partners to achieve these aims by developing standards ...